CRMDCorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an an…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 CorMedix (CRMD) Q2 2026 Earnings Call Transcript DefenCath revenue hit $66.1M as CorMedix expands dialysis partnerships and advances REZZAYO. | ||
 Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Trade The consensus price target hints at a 66% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. | ||
 CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains CorMedix stock rises 15% after Q2 earnings and revenues beat estimates, driven by solid DefenCath utilization and contributions from the Melinta portfolio. | ||
 CorMedix Inc. Q2 2026 Earnings Call Summary Moby summary of CorMedix Inc.'s Q2 2026 earnings call | ||
Cormedix Inc (CRMD) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised EBITDA ... DefenCath sales and the Melinta portfolio drive a 157% revenue surge, while a new LDO agreement expands market reach. | ||
 CorMedix Q2 Earnings Call Highlights CorMedix (NASDAQ:CRMD) reported second-quarter 2026 consolidated revenue of $101.9 million and adjusted EBITDA of $58.7 million, while reaffirming its full-year revenue outlook and raising adjusted EBITDA guidance. The company also said it signed a multiyear commercial supply agreement for DefenCath | ||
 CorMedix CEO Expects Supplemental Filing For Fungal Disease Treatment By Q3 – CRMD Stock Sees Best Day In Nearly 10 Months After Earnings Beat CorMedix expects to submit its supplemental Rezzayo application in Q3, with a potential FDA decision in the first half of 2027. | ||
 CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates CorMedix (CRMD) delivered earnings and revenue surprises of +11.54% and +7.64%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of -60.00% and -70.79%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates Syndax (SNDX) delivered earnings and revenue surprises of -22.22% and -11.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
IInsider Monkey | ||